3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
6
Thoracic
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
17
Surveys and Questionnaires
12
Specimen Handling
11
Docetaxel
11
Nivolumab
9
Interviews as Topic
9
Standard of Care
8
Gemcitabine
8
Early Intervention, Educational
8
olaparib
7
enzalutamide
7
Magnetic Resonance Spectroscopy
7
Psychiatric Rehabilitation
6
Paclitaxel
6
durvalumab
5
Trastuzumab
5
Radiotherapy
5
Ipilimumab
5
Carboplatin
5
Bevacizumab
5
pertuzumab
4
palbociclib
4
cabozantinib
4
atezolizumab
4
abiraterone
4
Therapeutics
4
Taxes
4
Oxaliplatin
4
Methods
4
Immunoglobulin G
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
AZD5305
×
Gastrointestinal
×
Clear all
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled